Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Nonmalignant Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 2 month's history of nonmalignant pain, currently in stable pain control on opioid therapy.~* Good, very good or excellent pain control on current opioid therapy.~* Willing and able to use a telephone interactive voice response service.~Exclusion Criteria:~* Currently receiving daily morphine or oxycodone monotherapy.~* Scheduled for surgery of the disease site (eg, major joint replacement surgery), or any other major surgery, which would fall within the study period.~Other protocol-specific exclusion/inclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BTDS (5, 10 or 20) (Type: EXPERIMENTAL): Buprenorphine transdermal patch
- Placebo to match BTDS (Type: PLACEBO_COMPARATOR): Placebo to match buprenorphine transdermal patch

Based on this trial design, predict the completion outcome and termination type (if applicable).